BAMLANIVIMAB

eli lilly canada inc🇨🇦 Health Canada

Approval Id: 6961cb2a408bfb4a
Drug Approval Canada Name: BAMLANIVIMAB
Product Name: BAMLANIVIMAB
Status: Cancelled Post Market
Status Date: 2023-02-13
Original Market Date: 2020-12-24
Din: 02508176
Drug Class: Human
Dosage Form: Solution
Route Of Administration: Intravenous
Schedule: COVID-19 - IO - Authorization , Schedule D , Prescription
Ahfs: 08:18.24
Atc Original: J06B IMMUNOGLOBULINS
Atc Name: j 06 b
Aig Number: 0162600002
Company Name: eli lilly canada inc
Company Address: SUITE 900, Exchange Tower, 130 King Street West, Toronto, Ontario, Canada, M5X 1B1

BAMLANIVIMAB

700 MG / 20 ML

Authorized

Agency

Health Canada

Country

🇨🇦

Approval Date

Jul 4, 2025

Approval ID

6961cb2a408bfb4a

Type

Standard